European Commission approves Enerzair Breezhaler (indacaterol acetate, glycopyrronium bromide and mometasone furoate) for uncontrolled asthma

The inhaler is approved as maintenance treatment of asthma in adults not adequately controlled with a maintenance combination of a long-acting beta2-agonist and a high-dose inhaled corticosteroid, and who experienced one or more asthma exacerbations in the previous year.

PharmaTimes